238 related articles for article (PubMed ID: 24324698)
1. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
[TBL] [Abstract][Full Text] [Related]
2. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kurahashi H; Morita M; Kugita M; Hiki Y; Aukema HM; Yamaguchi T; Calvet JP; Wallace DP; Nagao S
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F465-74. PubMed ID: 21147840
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease.
Goto M; Hoxha N; Osman R; Wen J; Wells RG; Dell KM
J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):639-44. PubMed ID: 20400910
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
5. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
[TBL] [Abstract][Full Text] [Related]
6. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD.
Mason SB; Liang Y; Sinders RM; Miller CA; Eggleston-Gulyas T; Crisler-Roberts R; Harris PC; Gattone VH
Anat Rec (Hoboken); 2010 Aug; 293(8):1279-88. PubMed ID: 20665806
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.
Jia G; Kwon M; Liang HL; Mortensen J; Nilakantan V; Sweeney WE; Park F
Pediatr Nephrol; 2010 Jun; 25(6):1139-46. PubMed ID: 20229187
[TBL] [Abstract][Full Text] [Related]
8. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF
Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
[TBL] [Abstract][Full Text] [Related]
9. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
10. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease.
Goto M; Hoxha N; Osman R; Dell KM
Pediatr Nephrol; 2010 Dec; 25(12):2449-57. PubMed ID: 20798958
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
Kugita M; Nishii K; Yamaguchi T; Suzuki A; Yuzawa Y; Horie S; Higashihara E; Nagao S
PLoS One; 2017; 12(5):e0177934. PubMed ID: 28542433
[TBL] [Abstract][Full Text] [Related]
12. Feeding soy protein isolate and n-3 PUFA affects polycystic liver disease progression in a PCK rat model of autosomal polycystic kidney disease.
Maditz KH; Benedito VA; Oldaker C; Nanda N; Lateef SS; Livengood R; Tou JC
J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):467-73. PubMed ID: 25822773
[TBL] [Abstract][Full Text] [Related]
13. Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
Sato Y; Qiu J; Hirose T; Miura T; Sato Y; Kohzuki M; Ito O
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G464-G473. PubMed ID: 33439105
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions.
Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y
Toxicology; 2011 Jan; 279(1-3):91-9. PubMed ID: 20888384
[TBL] [Abstract][Full Text] [Related]
15. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
[TBL] [Abstract][Full Text] [Related]
16. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
[TBL] [Abstract][Full Text] [Related]
17. Effects of Long-Term Exercise on Liver Cyst in Polycystic Liver Disease Model Rats.
Sato Y; Qiu J; Miura T; Kohzuki M; Ito O
Med Sci Sports Exerc; 2020 Jun; 52(6):1272-1279. PubMed ID: 31880641
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats.
Jiang L; Fang P; Septer S; Apte U; Pritchard MT
Int J Toxicol; 2018; 37(4):308-326. PubMed ID: 29862868
[TBL] [Abstract][Full Text] [Related]
19. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.
Park F; Sweeney WE; Jia G; Akbulut T; Mueller B; Falck JR; Birudaraju S; Roman RJ; Avner ED
Am J Physiol Renal Physiol; 2009 Mar; 296(3):F575-82. PubMed ID: 19129252
[TBL] [Abstract][Full Text] [Related]
20. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD).
Gao Y; Erokwu BO; DeSantis DA; Croniger CM; Schur RM; Lu L; Mariappuram J; Dell KM; Flask CA
NMR Biomed; 2016 Jan; 29(1):84-9. PubMed ID: 26608869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
